US FDA lifts hold on Inovio's cancer vaccine trials after firm answers device questions
Inovio Pharmaceuticals has started Phase III trials of its DNA-based human papillomavirus therapy VGX-3100 after the US FDA lifted a clinical hold imposed list year.